Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
6.55 (1y: +283%)
Market Cap 1.99 B P/E(ttm)
Enterprise Value 2.3 B P/B
MNKD- NAS (USA)
MannKind Corporation
Not Rated
Top Ranked Predictable Companies
$6.55
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt 0.186
MNKD's Cash to Debt is ranked lower than
95% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 46.63 vs. MNKD: 0.186 )
MNKD' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.19
Equity to Asset -0.44
MNKD's Equity to Asset is ranked lower than
95% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. MNKD: -0.44 )
MNKD' s 10-Year Equity to Asset Range
Min: -1.57   Max: 0.75
Current: -0.44
-1.57
0.75
Z-Score: -15.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -419885.70
MNKD's Operating margin (%) is ranked lower than
99% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -31.50 vs. MNKD: -419885.70 )
MNKD' s 10-Year Operating margin (%) Range
Min: -3073570   Max: -15273.6
Current: -419885.7
-3073570
-15273.6
Net-margin (%) -483903
MNKD's Net-margin (%) is ranked lower than
99% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -29.90 vs. MNKD: -483903 )
MNKD' s 10-Year Net-margin (%) Range
Min: -2931900   Max: -14799.1
Current: -483903
-2931900
-14799.1
ROA (%) -67.4
MNKD's ROA (%) is ranked lower than
85% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. MNKD: -67.4 )
MNKD' s 10-Year ROA (%) Range
Min: -107.3   Max: -42.7
Current: -67.4
-107.3
-42.7
ROC (Joel Greenblatt) (%) -92.70
MNKD's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MNKD: -92.70 )
MNKD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -414.1   Max: -81.2
Current: -92.7
-414.1
-81.2
EBITDA Growth (%) -29.1
MNKD's EBITDA Growth (%) is ranked lower than
91% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MNKD: -29.1 )
MNKD' s 10-Year EBITDA Growth (%) Range
Min: -29.1   Max: -1.9
Current: -29.1
-29.1
-1.9
EPS Growth (%) -25.1
MNKD's EPS Growth (%) is ranked lower than
89% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MNKD: -25.1 )
MNKD' s 10-Year EPS Growth (%) Range
Min: -25.1   Max: -1.9
Current: -25.1
-25.1
-1.9
» MNKD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

MNKD Guru Trades in Q2 2012

Jim Simons 450,503 sh (+12.81%)
» More
Q3 2012

MNKD Guru Trades in Q3 2012

Jim Simons Sold Out
» More
Q4 2012

MNKD Guru Trades in Q4 2012

Jean-Marie Eveillard 800,000 sh (New)
» More
Q1 2013

MNKD Guru Trades in Q1 2013

Jim Simons 1,354,116 sh (New)
Jean-Marie Eveillard Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MNKD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-03-31 Sold Out 0.01%$2.31 - $3.56 $ 6.55138%0
Jean-Marie Eveillard 2012-12-31 New Buy0.01%$1.85 - $2.83 $ 6.55203%800000
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/S 16925.20
MNKD's P/S is ranked lower than
100% of the 391 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. MNKD: 16925.20 )
MNKD' s 10-Year P/S Range
Min: 0   Max: 17700.5
Current: 16925.2
0
17700.5
EV-to-EBIT 11.8
MNKD's EV-to-EBIT is ranked lower than
92% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. MNKD: 11.8 )
MNKD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 11.8

Valuation & Return

vs
industry		 vs
history

Business Description

MannKind Corporation was incorporated in the State of Delaware. It is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. The Company's lead product candidate, AFREZZA (insulin human [rDNA origin]) inhalation powder, is an ultra rapid-acting insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Diabetes is a significant health concern. The Company's lead product candidate, AFREZZA, has a time-action profile unlike other insulin products. In its clinical trials to date, it has consistently observed that AFREZZA inhalation powder is rapidly absorbed into the bloodstream following inhalation, reaching peak levels within 12 to 14 minutes. In this manner, AFREZZA produces a profile of insulin levels in the bloodstream that closely approximates the early insulin secretion normally seen in healthy individuals immediately following the beginning of a meal, but which is absent in patients with diabetes. The AFREZZA inhalation powder is centered on a class of pH-sensitive organic molecules that self-assemble into small particles under acidic conditions. It refers to these particles as Technosphere particles. Certain drugs, such as insulin, can be loaded onto these particles by combining an acidic solution of the drug with a suspension of Technosphere material, which is then dried to a powder. This powder is then filled into plastic cartridges and packaged. To administer AFREZZA inhalation powder, a patient loads a cartridge into its inhaler. By inhaling through this device, air is pulled through the cartridge, which aerosolizes the powder and pulls the particles into the air current and out through the mouthpiece. The individual particles within this aerosol are small and have aerodynamic properties that enable them to fly efficiently deep into the lungs. When the particles contact the moist lung surface with its neutral pH, the Technosphere particles dissolve immediately, releasing the insulin molecules to diffuse across a thin layer of cells into the bloodstream. The FDA and comparable regulatory agencies in state, local and foreign jurisdictions impose substantial requirements upon the clinical development, manufacture and marketing of medical devices and new drug and biologic products.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:NNF1.Germany
» More Articles for MNKD

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD Jul 09 2012 
Weekly Top Insider Buys: HRB, LPI, GCO, GAM, SONC, MNKD Jul 09 2012 
Canadian Guru Francis Chou Buys Bank of America Warrants, Citigroup, Sears, Feb 16 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
The Details of the Afrezza Approval Delay Jan 31 2012 
MannKind’s Afrezza Was to Be Approved; What Happened Next? Jan 30 2012 
Why MannKind merits your attention? Jan 30 2012 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Canadian Value Investor Francis Chou Buys Abitibibowater, Bank Of America Warrants, Wells Fargo Warr Feb 16 2011 
MannKind: Deja Vu for the FDA and Afrezza Dec 29 2010 

More From Our Partners
Market Wrap for Thursday, May 23: Wall Street Shrugs Off Global Slump May 23 2013 - BENZINGA

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial